Las Vegas, NV -- (SBWIRE) -- 03/27/2013 -- AMARANTUS BIOSCI INC (OTC:AMBS) has received favorable preclinical results for MANF, rat model for the treatment of Parkinson' disease.
Amarantus BioSci management is contented with the current results achieved in preclinical data. The scientists are now confident about the efficiency of MANF and certain about it dominance over GDNF.
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein specifically developed to correct the folding that leads to death of cell. MANF is considered to be of great potential because it is developed by the body as well for the prevention of cell death. Amarantus BioSci is trying to use the same technology to provide the body with required amount of Mesencephalic-Astrocyte when required for the cell protection. The company has the intellectual property rights for the technology.
Currently the company's primary focus is on treatment of Parkinson' disease. But Traumetic brain injury, ultra-rare orphan disease and myocardial infarction are also in company's broad spectrum.
To find out what OTCMAGIC projects for Amarantus BioSci Inc for both short term and long term please click here: AMBS
OTCMAGIC Spends all day scouring the markets for the next huge Penny Stock Winner. Investors have come to trust us for our up to date commentary on all hot stocks so please visit OTCMAGIC right now and see what it's all about for yourself! At 30,000 Visitors a Month and growing rapidly OTCMAGIC is the hottest thing in Stock picks!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://OTCMagic.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers.